trending Market Intelligence /marketintelligence/en/news-insights/trending/mbrcuhmij4rw6qii11z2ya2 content esgSubNav
In This List

Aileron Therapeutics CEO resigns; interim replacement named

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Aileron Therapeutics CEO resigns; interim replacement named

Joseph Yanchik III resigned as president, CEO and director of Aileron Therapeutics Inc.

The clinical-stage biopharmaceutical company named John Longenecker as interim CEO. Longenecker is the founder and president of JPL Biotech, a biopharma/pharmaceutical consulting company.